Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases. The analysts view the company's lead program, Nomlabofusp, as a differentiated, disease-modifying therapy that targets the key pathogenic mechanism of frataxin (FXN) deficiency in Friedreich's ataxia (FA). Lower FXN levels predict early onset, disease severity, and faster progression. Friedreich's ataxia is a rare neurodegenerative disease affecting ~20, ...